GRAd-COV2

AXP000177.1 · Vaccine

Platform
gorilla adenovirus (GRAd, non-replicating)
Targets
SARS-CoV-2 S
Originator
ReiThera
Sponsor
ReiThera

Names

NameTypeSource
GRAd-COV2preferred name, codecurator, ctgov
ReiThera COVID-19 vaccine ambiguoussynonymctgov

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
gorilla adenovirus
Replication
non replicating
Modifications
non-replicating great ape (gorilla) adenovirus vector encoding the SARS-CoV-2 spike
Transgenes
SARS-CoV-2 spike
Route
intramuscular
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04791423Study of GRAd-COV2 for the Prevention of COVID-19 in AdultsCompletedPhase 2/32021-03-152021-06-0410300Covid19
NCT04528641Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 VaccineCompletedPhase 12020-08-102021-05-1998COVID-19

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 37315558GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.Cell reports. Medicine2023cited by trial NCT04791423
PMID 33895322Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.Molecular therapy : the journal of the American Society of Gene Therapy2021cited by trial NCT04528641

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41746078Non-Clinical Safety of GRAd Vector-Based COVID-19 and HIV Vaccines Supports a Platform Regulatory Approach.Vaccines2026name in abstract: GRAd-COV2
PMID 34698501GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults.Science translational medicine2022name in title: GRAd-COV2
PMID 36153335Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.NPJ vaccines2022name in title: GRAd-COV2
PMID 34737309Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19.NPJ vaccines2021name in title: GRAd-COV2

Notes

Single-dose non-replicating gorilla (great ape) adenovirus vector encoding the SARS-CoV-2 spike. The COVITAR trial (NCT04791423) was a completed phase 2/3 study of 10,300 participants, so the program meets the phase 3 bar; never authorised. The vector is usually reported as GRAd32, which the source read does not confirm, so the strain cell is left empty.

How to cite

GRAd-COV2 (AXP000177.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000177.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.